The Tumour Marker Group

Trine BjøroGroup leader
Trine Bjøro
Group leader

Immunoassay techniques have revolutionized the determination of clinically relevant proteins and peptides. The Tumour Marker Group at MBK is one of the few hospital laboratories that still develops, validates and introduces novel “in-house” assays into the clinical routine. We have more than 25 years of experience in the production of monoclonal antibodies (mAbs) for use in the construction of these specialized assays. Many of our mAbs have been licensed and are used in the manufacture of commercial assay kits that are in worldwide use. The challenges related to immunometric assays, particularly the problems caused by heterophilic antibodies or human anti-mouse antibodies have been thoroughly studied by the group and we have undertaken extensive studies on the incidence and prevention of interference in immunometric assays. We have developed assays for measuring therapeutic antibodies used in the treatment of patients with autoimmune diseases such as rheumatoid arthritis and Crohn’s disease, and participate in several national clinical trials. Recently, we have also developed assays for checkpoint (PD-1, CTLA-4) inhibitors, the new blockbuster drugs used in immunotherapy in oncology. By monitoring serum concentrations of these effective and expensive drugs, and identifying patients who produce neutralizing antibodies, clinicians may optimize the treatment for each individual patient.

Research projects

  • Development and validation of immunoassays for novel immunotherapy drugs such as KEYTRUDA (pembrolizumab), OPDIVO (nivolumab) and YERVOY (ipilimumab), for monitoring drug levels in patients with lung cancer and malignant melanoma.
  • Developing assays for measuring different monoclonal antibodies used in the treatment of patients with autoimmune diseases. These assays are used in the clinical routine and in several ongoing clinical trials.
  • Detection of antibodies to transglutaminase in the HUNT4-cohort using an in-house dual label assay in collaborative study “Coeliac disease in HUNT”.
  • Late effects after testicular cancer; thyroid and kidney function, in collaboration with National Advisory Unit on Late Effects after Cancer Treatment.
  • Screening for patient antibodies to HH1, a novel antibody-based drug used in lymphoma clinical trials (Lymrit).
  • Part of the collaboration study “Hallmarks in lung cancer”; validating different markers for potential development of assays clinically useful indaily practice.
  • Investigating the potential effect of combinatorial treatment of melanoma with PLX4032 (vemurafenib) and HER antibodies (in vitro studies).
  • Validating immunoassays for human epidermal growth factor receptors 2, 3 and 4 as tumour markers for HER2 positive breast cancer.

Contact information
Group leader professor Trine Bjøro, Department of Medical Biochemistry Oslo University Hospital, Radiumhospitalet Tel: +47 22935906 E-mail: bjc@ous-hf.no